TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35968287
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (NRT)
Study: 36454906
Drug: Blueberry (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry (250 g)
Study: 38762798
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen
Study: 33787042
Drug: Pectin-containing enteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin-containing enteral formula (Hine E-Gel®)
Study: 35870947
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (1 g Taurine, n = 60)
Study: 38628260
Drug: Pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy
Study: 33033101
Drug: Vedolizumab 300
Normalized name: vedolizumab 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab 300 mg
Study: 36399081
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control (no implants)
Study: 39758967
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: 33652093
Drug: Hospice representatives
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hospice representatives reporting missing opioid medications
Study: 33652093
Drug: Hospice representatives
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hospice representatives reporting disposal practices of medications after home deaths
Study: 33187916
Drug: Concurrent apatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent apatinib and brain radiotherapy (BR)
Study: 33199417
Drug: Semaglutide 0.5
Normalized name: semaglutide 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 0.5 mg
Study: 36801984
Drug: Semaglutide 1.0
Normalized name: SEMAGLUTIDE 1.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [WEGOVY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 1.0 mg
Study: 34255168
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics in combination with cognitive remediation therapy (AP + CR)
Study: 34255168
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (AP)
Study: 35050837
Drug: RVT-1601 10
Normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVT-1601 10 mg
Study: 35050837
Drug: RVT-1601 40
Normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVT-1601 40 mg
Study: 35050837
Drug: RVT-1601 80
Normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVT-1601 80 mg
Study: 36149171
Drug: Pelvic stabilization
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic stabilization exercises and TENS administered once daily for approximately 30 min during acute hospitalization
Study: 32937192
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal Oxytocin (24 IU)
Study: 36343030
Drug: Intravascular irradiation
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular irradiation of blood (ILIB) combined with myofunctional exercises; ILIB treatment is performed twice a week for 8 weeks.
Study: 36343030
Drug: Placebo ILIB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ILIB combined with orofacial myofunctional therapy (MFT) exercise protocol; placebo treatment is performed twice a week for 8 weeks.
Study: 35662408
Drug: Furmonertinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furmonertinib (80 mg/day)
Study: 36193750
Drug: Guideline-Directed Medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-Directed Medical Therapy (GDMT) goals achieved
Study: 34731918
Drug: Infiltration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration with anesthetic solution and adjuvants (fentanyl, epinephrine, ketorolac)
Study: 35881302
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without SDF treatment)
Study: 34656740
Drug: Adjuvant abemaciclib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant abemaciclib combined with endocrine therapy (ET) for 2 years
Study: 35477480
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blockers with standard care
Study: 32178925
Drug: Basiliximab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (20 mg D0 and D4)
Study: 32178925
Drug: Thymoglobulin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin (3 mg/kg total)
Study: 32673243
Drug: Smartphone-based vision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based vision screening solution
Study: 35041775
Drug: Brigatinib 180
Normalized name: brigatinib 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 180 mg once daily (7-day lead-in dose at 90 mg once daily)
Study: 32845740
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg galcanezumab (240 mg loading dose)
Study: 32845740
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg galcanezumab
Study: 35048733
Drug: Rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation therapy plus optional delayed ACL reconstruction
Study: 38325518
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy (DBT)
Study: 36978099
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy
Study: 36288558
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine hydrochloride gel
Study: 35166384
Drug: Fructans (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructans (40 g/500 mL saline)
Study: 35166384
Drug: Glucose (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (40 g/500 mL saline)
Study: 35166384
Drug: Saline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (500 mL)
Study: 32186106
Drug: Gua Sha
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Gua HC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gua Sha therapy
Study: 35964137
Drug: Gln/Arg/HMB supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gln/Arg/HMB supplementation (2 sachets daily: 7 g l-arginine, 7 g l-glutamine, 1.5 g HMB)
Study: 32784930
Drug: Tetrodotoxin (TTX)
Normalized name: Tetrodotoxin
DrugBank: Tetrodotoxin (DB05232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrodotoxin (TTX) 15 µg
Study: 32784930
Drug: Tetrodotoxin (TTX)
Normalized name: Tetrodotoxin
DrugBank: Tetrodotoxin (DB05232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrodotoxin (TTX) 45 µg
Study: 34116816
Drug: DynamiCare along
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: DynamiCare along with treatment-as-usual (TAU; N = 29)
Study: 39164933
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT)
Study: 38149636
Drug: Family-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based treatment (FBT)
Study: 33452887
Drug: Clorpactin 0.4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorpactin 0.4% solution
Study: 34734835
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual alone
Study: 32093665
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) oxygen therapy (50 L/min, FiO2 0.5)
Study: 32093665
Drug: Venturi mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venturi mask (VM) oxygen therapy (15 L/min, FiO2 0.5)
Study: 32093665
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) oxygen therapy (50 L/min, FiO2 0.5) in good responders
Study: 34134520
Drug: Statin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin monotherapy
Study: 35258371
Drug: Doxorubicin drug-eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin drug-eluting bead (DEB) TACE
Study: 35850136
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (50 minutes along with conventional medical treatment)
Study: 32200610
Drug: CFNB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFNB with basal infusion of ropivacaine plus boluses (Group III)
Study: 32200610
Drug: CFNB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFNB with continuous infusion of ropivacaine (Group II)
Study: 34158317
Drug: R2-GDP treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: R2-GDP treatment (rituximab, gemcitabine, dexamethasone, and cisplatin)
Study: 34158317
Drug: R2-GDP treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: R2-GDP treatment
Study: 37431464
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (control group)
Study: 33373678
Drug: Regular coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular coffee (200 mg caffeine at breakfast and 100 mg caffeine after lunch)
Study: 35418281
Drug: Ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.3 mg (n = 23)
Study: 35351048
Drug: Iconic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iconic therapy (IT)
Study: 33773631
Drug: β‐lactam treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐lactam treatment
Study: 32777193
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (2 mg/kg/day) alone
Study: 32777193
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (2 mg/kg/day) plus budesonide nebulization (0.5 mg every 12 h)
Study: 34791074
Drug: Fosfomycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin (3 gr once daily for 10 days)
Study: 34791074
Drug: Ciprofloxacin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (0.5 gr twice daily for 10 days)
Study: 35902297
Drug: Paclitaxel 65
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 65 mg/m2 plus pazopanib 600–800 mg daily
Study: 35902297
Drug: Standard weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weekly paclitaxel 80 mg/m2
Study: 35902297
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Paclitaxel plus pazopanib)
Study: 34396246
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg
Study: 35462214
Drug: Plantar vibration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plantar vibration therapy at 80Hz and conventional physical therapy (CPT) for 4 weeks
Study: 35462214
Drug: Plantar vibration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plantar vibration therapy at 80Hz and CPT for 4 weeks
Study: 37950162
Drug: Microrelin 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microrelin 3.75 mg
Study: 32613714
Drug: Intensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive periodontal treatment (IPT; scaling and root planing plus azithromycin 500 mg every day for 3 days)
Study: 32613714
Drug: Minimal periodontal
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal periodontal treatment (MPT; supragingival professional mechanical plaque removal plus a placebo)
Study: 32544852
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (HPD) with adjunctive prebiotic, probiotic, or synbiotic
Study: 34511165
Drug: Parent-child painting
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-child painting and creative crafting therapy in addition to applied behavior analytic intervention
Study: 32168208
Drug: Thyroxine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine therapy
Study: 36244667
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) supplementation (0.6 μg/kg)
Study: 34415933
Drug: Maternal antiretroviral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal antiretroviral therapy (mART) containing tenofovir/emtricitabine plus lopinavir/ritonavir
Study: 39665506
Drug: Haloperidol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2 mg)
Study: 35416909
Drug: Once-daily fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily fixed-dose triple combination pill
Study: 34259405
Drug: Femoston (estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoston (estradiol tablets/estradiol and dydrogesterone tablets, 1 tablet per day) for 3 menstrual cycles.
Study: 33879218
Drug: Curcumin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (80 mg based on body surface)
Study: 37700348
Drug: Salvage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage treatment
Study: 36310566
Drug: PPI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI therapy
Study: 32449311
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment only
Study: 33945439
Drug: One booster
Normalized name: Acetylcysteine/Ascorbic Acid/Asparagus/Garlic/Glutamine/Glutathione/Glycine/Milk Thistle Extract/Riboflavin/Selenium/Thioctic Acid/Vitamin E 100 MCG-100 MG-12.5 MG-50 MG-25 MG-5 MG-25 MG-70 MG-2.5 MG-100 MCG-25 MG-50 IU Oral Capsule [GLUTATHIONE BOOSTER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: One booster dose of Kanghua HDCV
Study: 33945439
Drug: Two booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two booster doses of Kanghua HDCV
Study: 39141382
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion
Study: 33661675
Drug: Trauma-focused cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive-behavioral therapy (TF-CBT), mean of 15 sessions over 25 weeks
Study: 32842183
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment once a day for 10 consecutive days (20 treatments total)
Study: 32842183
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment twice per day for a total of 10 days
Study: 32842183
Drug: No hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hyperbaric oxygen therapy (control group)
Study: 33089005
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch
Study: 35688053
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous flumazenil infusions (4 mg/24 h for approximately eight days)
Study: 35970035
Drug: S-IROX (S-1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-IROX (S-1, irinotecan, and oxaliplatin combination therapy)
Study: 33129705
Drug: Analgesic medication
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic medication only
Study: 32592414
Drug: Solution‐Oriented Approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution‐Oriented Approach Intervention (SOAI)
Study: 32366328
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus Proactive Psychological Medicine (PPM)
Study: 33524368
Drug: Guselkumab (IL-23p19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab (IL-23p19 blocker)
Study: 34563924
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy only
Study: 33325311
Drug: Family engagement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family engagement in treatment
Study: 33325311
Drug: Opioid Assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid Assisted Treatment (OAT)
Study: 34957550
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) treatment, mean modal dose 27 mg/kg/day, median treatment time 267 days (range 18-910).
Study: 39499309
Drug: Paracetamol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1000 mg
Study: 35785498
Drug: Licorice root
Normalized name: Licorice Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licorice root extract (1,000 mg/day)
Study: 32990794
Drug: Leucocyte-poor-platelet-rich plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucocyte-poor-platelet-rich plasma (PRP) injection at the end of surgery in group B.
Study: 32990794
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PRP injection).
Study: 34656119
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg twice daily
Study: 33523763
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (PJ) 300 mL daily for 2 weeks
Study: 34608673
Drug: Maxillary sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary sinus floor augmentation (MSFA)
Study: 33951361
Drug: Liraglutide group
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide group (liraglutide 3.0 mg per day plus usual activity)
Study: 33951361
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (exercise program plus liraglutide therapy)
Study: 39054476
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group
Study: 32227717
Drug: Wuziyanzong Pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuziyanzong Pills at 6 g bid for 4 weeks
Study: 34904950
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (VSL#3) for 4 weeks (2 × 450 billion colony-forming units per day)
Study: 34936531
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for 6 months
Study: 38507976
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) therapy
Study: 32396668
Drug: Web-based film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based film about oral health (8.5 minutes duration)
Study: 34812466
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g FDSP
Study: 34812466
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g FDSP
Study: 32323706
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration
Study: 32976576
Drug: Pomalidomide 2
Normalized name: pomalidomide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 2 mg per day (starting at 0.5 mg per day increasing to 2 mg per day over 6 weeks)
Study: 32976576
Drug: Pomalidomide (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (high-dose cohort)
Study: 33186898
Drug: New Zealand
Normalized name: NEW ZEALAND GREEN MUSSEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Zealand blackcurrant extract 600 mg/day
Study: 33186898
Drug: New Zealand
Normalized name: NEW ZEALAND GREEN MUSSEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Zealand blackcurrant extract 300 mg/day
Study: 35324095
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment
Study: 34391310
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (3 J/cm²) plus drug therapy (Group 2)
Study: 32503599
Drug: Fluticasone furoate/umeclidinium/vilanterol
Normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg
Study: 34616111
Drug: Quercetin-rich onion
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin-rich onion (daily quercetin intake, 50 mg as aglycone equivalent)
Study: 32197614
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication treatment
Study: 33274663
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg lorazepam
Study: 38683479
Drug: Upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 15 mg once daily
Study: 32535600
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (P)
Study: 33013294
Drug: Osteopathic Manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic Manipulative Treatment (OMT)
Study: 33861329
Drug: Loving-kindness meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loving-kindness meditation (n = 91); 12 weekly 90-minute group sessions.
Study: 35307465
Drug: ADD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADD group (pecans 68 g)
Study: 34732491
Drug: Duloxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine treatment (60 mg/day for 7 weeks)
Study: 34732491
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (no additional treatment)